Journal of the Formosan Medical Association
Volume 105, Issue 9 , Pages 743-752 , 2006

Safety and Effectiveness of Rosiglitazone in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease

Received 18 October 2005 ,Revised 4 November 2005 ,Accepted 7 March 2006.

References 

  1. Matteoni CA , Younossi ZM , Gramlich T , et al.   Nonalcoholic fatty liver disease: a spectrum of clinical pathological severity . Gastroenterology . 1999;116:1413–1419
  2. Festi D , Colecchia A , Sacco T , et al.   Hepatic steatosis in obese patients: clinical aspects and prognostic significance . Obes Rev . 2004;5:27–42
  3. Marchesini G , Brizi M , Morselli-Labate AM , et al.   Association of nonalcoholic fatty liver disease with insulin resistance . Am J Med . 1999;107:450–455
  4. Chitturi S , Abeygunasekera S , Farrell GC , et al.   NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome . Hepatology . 2002;35:373–379
  5. Marchesini G , Bugianesi E , Forlani G , et al.   Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome . Hepatology . 2003;37:917–923
  6. Salt WB . Nonalcoholic fatty liver disease (NAFLD): a comprehensive review . J Insur Med . 2004;36:27–41
  7. Phillips LS , Grunberger G , Miller E , et al.   Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes . Diabetes Care . 2001;24:308–315
  8. Lebovitz HE , Dole JF , Patwardhan R , et al.   Rosiglitazone monotherapy is effective in patients with type 2 diabetes . J Clin Endocrinol Metab . 2001;86:280–288
  9. Miyazaki Y , Mahankali A , Matsuda M , et al.   Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone . Diabetes Care . 2001;24:710–719
  10. Mayerson AB , Hundal RS , Dufour S , et al.   The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes . Diabetes . 2002;51:797–802
  11. Miyazaki Y , Mahankali A , Matsuda M , et al.   Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients . J Clin Endocrinol Metab . 2002;87:2784–2791
  12. Carey DG , Cowin GJ , Galloway GJ , et al.   Effect of rosiglita-zone on insulin sensitivity and body composition in type 2 diabetic patients . Obes Res . 2002;10:1008–1015
  13. Bajaj M , Suraamornkul S , Pratipanawatr T , et al.   Pioglita-zone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes . Diabetes . 2003;52:1364–1370
  14. Neuschwander-Terri BA , Brunt EM , Wehmeier KR , et al.   Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-r ligand rosiglitazone . Hepatology . 2003;38:1008–1017
  15. Caldwell SH , Hespenheide EE , Redick JA , et al.   A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis . Am J Gastroenterol . 2001;96:519–525
  16. Tolman KG , Chandramouli J . Hepatotoxicity of the thiazo-lidinediones . Clin Liver Dis . 2003;7:367–379
  17. Lebovitz HE , Kreider M , Freed MI . Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction . Diabetes Care . 2002;25:815–821
  18. Rubin CJ , Schneider RL . Pioglitazone liver enzyme profiles is similar in placebo in US controlled clinical trials . Diabetes . 2000;49:A123
  19. Promrat K , Lutchman G , Uwaifo GI , et al.   A pilot study of pioglitazone treatment for non alcoholic steatohepatitis . Hepatology . 2004;39:188–196
  20. Matthews DR , Hosker JP , Rudenski AS , et al.   Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man . Diabetologia . 1985;28:412–419
  21. Dailey GE , Noor MA , Park JS , et al.   Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double blind trial . Am J Med . 2004;116:223–229
  22. Day C , James O . Steatohepatitis: a tale of two “hits”? . Gastroenterology . 1998;114:842–845
  23. Marceau P , Biron S , Hould FS , et al.   Liver pathology and the metabolic syndrome X in severe obesity . J Clin Endocrinol Metab . 1999;84:1513–1517
  24. Pavo I , Jermendy G , Varkonyi TT , et al.   Effect of pioglita-zone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes . J Clin Endocrinol Metab . 2003;88:1637–1645
  25. Hanefeld M , Brunetti P , Schernthaner GH , et al.   One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes . Diabetes Care . 2004;27:141–147
  26. Aronoff S , Rosenblatt S , Braithwaite S , et al.   Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes . Diabetes Care . 2000;23:1605–1611
  27. Kipnes MS , Krosnick A , Rendell MS , et al.   Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study . Am J Med . 2001;111:10–17
  28. Einhorn D , Rendell M , Rosenzweig J , et al.   Pioglita-zone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study . Clin Ther . 2000;22:1395–1409
  29. Aljabri K , Kozak SE , Thompson DM . Addition of pioglita-zone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial . Am J Med . 2004;116:230–235
  30. Miyazaki Y , Pipek R , Mandarino LJ , et al.   Tumor necrosis factor a and insulin resistance in obese type 2 diabetic patients . Int J Obesity . 2003;27:88–94
  31. Spiegelman BM . PPAR-?: adipogenic regulator and thia-zolidinedione receptor . Diabetes . 1998;47:507–514
  32. Tonelli J , Li W , Kishore P , et al.   Mechanism of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes . Diabetes . 2004;53:1621–1629
  33. Haffner SM , Greenberg AS , Weston WM , et al.   Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes melli-tus . Circulation . 2002;106:679–684
  34. Mohanty P , Aljada A , Ghanim H , et al.   Evidence for a potent antiinflammatory effect of rosiglitazone . J Clin Endocrinol Metab . 2004;89:2728–2735
  35. Natali A , Ferrannini E . Hypertension, insulin resistance, and the metabolic syndrome . Endocrinol Metab Clin North Am . 2004;33:417–429
  36. American Gastroenterological Association  . AGA technical review on nonalcoholic fatty liver disease . Gastroenterology . 2002;123:1705–1725
  37. Quinn SF , Gosink BB . Characteristic sonographic signs of hepatic infiltration . Am J Roentgenol . 1985;145:753–755
  38. Mulhall BP , Ong JP , Younossi ZM . Non-alcoholic fatty liver disease: an overview . J Gastroenterol Hepatol . 2002;17:1136–1143

PII: S0929-6646(09)60202-3

doi: 10.1016/S0929-6646(09)60202-3

Journal of the Formosan Medical Association
Volume 105, Issue 9 , Pages 743-752 , 2006

Article Tools